Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition

Abstract The objective was to correlate CD47 gene expression with resistance to immune checkpoint inhibitors (ICI) in tumor tissue of gynecological cancer (GC). Further, we sought to assess the efficacy of targeting CD47 pathway alone and in combination in pre-clinical ovarian cancer (OC) models. We...

Full description

Bibliographic Details
Main Authors: Hussein Al-Sudani, Ying Ni, Philip Jones, Huseyin Karakilic, Lei Cui, Lisa D. S. Johnson, Peter G. Rose, Alexander Olawaiye, Robert P. Edwards, Robert A. Uger, Gloria H. Y. Lin, Haider Mahdi
Format: Article
Language:English
Published: Nature Portfolio 2023-07-01
Series:npj Precision Oncology
Online Access:https://doi.org/10.1038/s41698-023-00418-4

Internet

https://doi.org/10.1038/s41698-023-00418-4

Similar Items